10-Q: NextPlat Q2 2025: Net Loss Narrows Amid Healthcare Revenue Decline

NextPlat Corp reported a narrower net loss in Q2 2025, driven by significant operating expense reductions, despite a substantial decline in healthcare segment revenue.

Summary

• Net loss attributable to NextPlat Corp significantly narrowed to $1.8 million for Q2 2025, a 66% improvement from $5.3 million in Q2 2024.
• Year-to-date net loss also improved by 54% to $3.1 million for H1 2025, compared to $6.8 million for H1 2024.
• Total revenue decreased by 22% to $13.2 million in Q2 2025 from $17.0 million in Q2 2024.
• Year-to-date revenue decreased by 19% to $27.8 million in H1 2025 from $34.5 million in H1 2024.
• e-Commerce segment revenue increased by 17% to $4.1 million in Q2 2025 and by 12% to $7.1 million in H1 2025, driven by hardware sales and favorable foreign currency impact.
• Healthcare segment revenue declined significantly, with pharmacy prescription revenue down 22% to $8.2 million in Q2 2025 (91,000 prescriptions vs. 133,000) and 340B contract revenue down 68% to $1.0 million.
• Gross profit margins decreased to 21.8% in Q2 2025 from 34.5% in Q2 2024, primarily due to declines in both operating segments.
• Total operating expenses decreased by 72% to $4.7 million in Q2 2025, largely due to the absence of a $9.8 million impairment loss recorded in Q2 2024.
• Cash balance stood at $16.6 million as of June 30, 2025, with working capital of $20.7 million.
• Net cash used in operating activities increased to $3.1 million for H1 2025 from $0.4 million for H1 2024.

Sentiment

Score: 4

Explanation: While the net loss narrowed significantly, this was primarily due to the absence of a large impairment charge from the prior year, not improved operational performance. Revenue declined substantially, gross profit margins compressed, and cash burn from operations increased. The company faces significant headwinds in its healthcare segment and geopolitical risks in e-commerce, despite some growth in e-commerce revenue. The overall financial health shows deterioration in key operational metrics.

Positives

• Net loss significantly narrowed by 66% in Q2 2025 and 54% in H1 2025 compared to the prior year periods.
• e-Commerce segment revenue grew by 17% in Q2 2025 and 12% in H1 2025, driven by hardware sales and favorable foreign currency exchange rates.
• Total operating expenses decreased substantially by 72% in Q2 2025 and 59% in H1 2025, primarily due to the absence of large impairment losses and reductions in salaries, wages, and professional fees.
• Stock-based compensation expense decreased significantly from $1.1 million in H1 2024 to $11,000 in H1 2025 due to non-recurring grants fully vested.
• Remediated a material weakness related to inventory valuation controls during fiscal 2024 by implementing formalized policies, senior management oversight, and enhanced data accuracy.
• Management believes existing cash resources of $16.6 million are sufficient to support planned operations for the next 12 months.

Negatives

• Total revenue decreased by 22% in Q2 2025 and 19% in H1 2025 compared to the prior year periods.
• Healthcare segment revenue experienced a substantial decline, with pharmacy prescription revenue down 22% in Q2 2025 (91,000 prescriptions vs. 133,000) and 340B contract revenue down 68%.
• Gross profit margins decreased significantly to 21.8% in Q2 2025 from 34.5% in Q2 2024, and to 22.9% in H1 2025 from 31.1% in H1 2024.
• Healthcare segment gross profit margins decreased to 19.9% in Q2 2025 from 35.2% in Q2 2024, attributed to decreased prescription volume and drug price increases outpacing reimbursement rates.
• e-Commerce segment gross profit margins decreased to 25.9% in Q2 2025 from 31.6% in Q2 2024, due to new airtime costs and temporary rate reductions for customers affected by service interruptions.
• Net cash used in operating activities increased significantly to $3.1 million for H1 2025 from $0.4 million for H1 2024, indicating higher cash burn from operations.
• Cash balance decreased from $19.96 million at December 31, 2024, to $16.64 million at June 30, 2025.
• The company is involved in multiple legal proceedings, including a class action lawsuit related to the Progressive Care merger and an EEOC lawsuit.

Risks

• U.S. and Chinese Tariffs: The current tariff environment has an immediate adverse impact on business, financial prospects, and profitability, and may materially and adversely impact the ability to be profitable.
• Trade Policy Risk: Retaliatory tariffs imposed by China expose the company to significant and ongoing trade-policy risk, complicating sales forecasting, inventory management, and production planning for the Chinese market.
• Regulatory Discretion: Chinese authorities have broad discretion to increase, decrease, or suspend tariff rates with little advance notice, and may target specific U.S. companies or industries for additional retaliatory action.
• Customer Concentration (e-Commerce): Amazon accounted for 31.1% of e-Commerce segment revenues for the six months ended June 30, 2025.
• Supplier Concentration (e-Commerce): Iridium Satellite (23.8%), Garmin (14.4%), and Globalstar (10.6%) accounted for significant portions of e-Commerce purchases for the six months ended June 30, 2025.
• Supplier Concentration (Healthcare): One vendor accounted for 96.9% of total vendor purchases for Healthcare Operations for the six months ended June 30, 2025.
• PBM Reimbursement Risk (Healthcare): Progressive Care's trade receivables are primarily from prescription medications billed to various insurance providers, with significant concentrations from three PBMs (A: 28%, B: 17%, C: 15%).
• Litigation Risk: The company is involved in several legal proceedings, including an EEOC lawsuit, a class action suit regarding the Progressive Care merger, and a potential claim from a former employee, with uncertain outcomes and potential for unspecified damages.
• Healthcare Industry Changes: Continued changes in provider relationships, shifts in patient flow due to insurance network adjustments, and provider decisions to align with different pharmacy partners can negatively impact pharmacy prescription volume.
• 340B Program Changes: Relationships transitioning to other pharmacy partners, covered entities opening in-house pharmacies, and entities no longer participating in the 340B program can significantly reduce 340B contract revenues.
• Drug Price vs. Reimbursement: Continued industry-wide impact of drug price increases outpacing reimbursement rate adjustments negatively affects gross profit margins in Healthcare Operations.
• Service Provider Contract Changes: Expiration of service provider airtime contracts and introduction of new costs, along with temporary rate reductions for customers affected by service interruptions, can negatively impact e-Commerce gross profit margins.

Future Outlook

Management is exploring various strategic alternatives to diversify business operations, including opportunities in additional services, joint ventures, and other collaborative structures. The company has paused certain initiatives within its e-Commerce development program aimed at the Chinese market, such as the launch of Florida Sunshine vitamins, due to U.S. and Chinese tariffs, but is reviewing opportunities to sell these products in other markets. The company intends to continue selling OPKO Health Europe products in China, which are not subject to additional tariffs.

Management Comments

• We continue to closely monitor our cash position and operating expenditures.
• In response to recent trends and in alignment with our long-term strategic goals, we continue to implement a series of cost reduction measures aimed at improving operational efficiency and preserving liquidity.
• While we remain committed to investing in key growth initiatives, we are prioritizing financial discipline to ensure we maintain adequate liquidity to support ongoing operations and strategic objectives.
• Management is exploring various options with respect to strategic alternatives to diversify our business operations, including opportunities in additional services, joint ventures, and other collaborative structures.
• Management believes that the existing financial resources are sufficient to continue operating activities for at least one year past the issuance date of the consolidated financial statements.
• The company's management does not believe that the Weisberg claim is meritorious and plans to vigorously defend against the suit.
• Management believes, based on discussions with its legal counsel, that Progressive Care has meritorious defenses against the former employee's claim.

Industry Context

The filing highlights challenges in the healthcare sector, specifically the impact of drug price increases outpacing reimbursement rate adjustments, which is a common industry-wide issue affecting pharmacy profitability. The decline in 340B contract revenue due to covered entities opening in-house pharmacies or transitioning relationships reflects competitive pressures and evolving dynamics within the 340B program. In e-commerce, the company faces geopolitical risks from U.S. and Chinese tariffs, which are broadly impacting international trade and supply chains, forcing companies to re-evaluate market entry strategies and product sourcing. The growth in e-commerce hardware sales and recurring airtime revenue suggests resilience in the satellite communication services niche, despite broader economic headwinds.

Management Changes

Corporate Governance

Legal Proceedings

• A former employee of Pharmco LLC filed a lawsuit on March 17, 2025, asserting claims under Equal Employment Opportunity Commission (EEOC) regulations. The company is vigorously defending the claims and cannot estimate the potential loss.
• Alan Jay Weisberg, former CEO and Chairman of Progressive Care Inc., filed a putative class action suit on October 28, 2024, against NextPlat, Charles M. Fernandez (late CEO), and Rodney Barreto. The suit alleges breach of fiduciary duty in connection with the Progressive Care merger, claiming insufficient consideration. The company believes the claim is not meritorious and is vigorously defending it, having filed a motion to dismiss.
• Progressive Care was notified on June 17, 2024, of a potential claim by a former employee alleging breach of an employment contract. Progressive Care filed a petition for arbitration, asserting the employee breached the contract, and believes it will prevail. The amount of loss cannot be reasonably estimated.

Related Party Transactions

• Amounts due to David Phipps, Interim Chief Executive Officer, for American Express accounts personally guaranteed by him, totaled approximately $1,000 as of June 30, 2025.
• Wages were paid to one employee related to Mr. Phipps and two employees related to Dr. Pamela Roberts (former COO of Progressive Care) during the six months ended June 30, 2025.
• Wages were paid to Lauren Sturges Fernandez, spouse of the late Chief Executive Officer Charles M. Fernandez, as Chief of Staff and Special Assistant to the Chairman of the Board during the six months ended June 30, 2025.

Stakeholder Impact

• Shareholders: Experience continued net losses, declining revenue, and reduced gross profit margins, which could negatively impact share price. The class action lawsuit related to the Progressive Care merger introduces uncertainty and potential financial liability.
• Employees: Termination of a key executive (Dr. Pamela Roberts) and a decrease in total headcount indicate ongoing restructuring and cost-cutting measures, potentially affecting employee morale and job security.
• Customers (Healthcare): Shifts in patient flow due to insurance network adjustments and provider decisions, along with covered entities transitioning from 340B contracts, suggest instability in customer relationships and service delivery.
• Customers (e-Commerce): Temporary rate reductions due to service interruptions could impact customer satisfaction, while tariff impacts on product availability and pricing in certain markets may affect purchasing decisions.
• Suppliers: High concentration with single vendors in both e-Commerce (Iridium, Garmin, Globalstar) and Healthcare (one vendor for 96.9% of purchases) creates dependency and potential risk if relationships sour or terms change.
• Creditors: The company's cash position is decreasing, and net cash used in operating activities is increasing, which could raise concerns about future liquidity, although management states current cash is sufficient for 12 months.

Next Steps

• Continue implementing cost reduction measures to improve operational efficiency and preserve liquidity.
• Explore various strategic alternatives to diversify business operations, including additional services, joint ventures, and collaborative structures.
• Review opportunities to sell Florida Sunshine products in markets other than China due to tariff impacts.
• Vigorously defend against ongoing legal proceedings, including the class action suit related to the Progressive Care merger and the EEOC lawsuit.
• Prosecute claims in arbitration against a former employee regarding an alleged breach of employment contract.

Key Dates

Recommendation

The company reported a significantly narrower net loss, which is a positive, but this improvement is largely attributable to the absence of a substantial impairment charge from the prior year, rather than a fundamental improvement in operational profitability. Revenue declined across the board, particularly in the healthcare segment, and gross profit margins compressed. While e-commerce revenue showed growth, it was offset by challenges in the larger healthcare segment and new tariff risks. The increased cash burn from operations and ongoing legal proceedings add to the uncertainty. Management's stated sufficiency of cash for the next 12 months provides some stability, and cost reduction measures are underway. However, the underlying operational trends are concerning. A "hold" recommendation is appropriate as the company navigates these challenges and attempts to diversify and optimize its business segments. Investors should monitor the effectiveness of cost-cutting, the impact of strategic alternatives, and the resolution of legal matters before considering further investment.

Keywords

e-Commerce, Healthcare Operations, Satellite Communication, Pharmacy, 340B Program, Tariffs, SEC Filing, Quarterly Report, Financial Results, Net Loss, Revenue, Operating Expenses, Nasdaq, NXPL, Progressive Care, Outfitter Satellite, Florida Sunshine Brands